Congenital disorders of glycosylation (CDG) are a rapidly growing family comprising >100 genetic diseases. Some 25 CDG are pure O-glycosylation defects. Even among this CDG subgroup, phenotypic diversity is broad, ranging from mild to severe poly-organ/system dysfunction. Ophthalmic manifestations are present in 60% of these CDG. The ophthalmic manifestations in N-glycosylation-deficient patients have been described elsewhere. The present review documents the spectrum and incidence of eye disorders in patients with pure O-glycosylation defects with the aim of assisting diagnosis and management and promoting research.
serine or threonine residue in the protein. This serine/threonine (Ser/Thr)-GalNAc structure forms the core of longer and more complex structures. 5 While many O-glycans are α-linked by a GalNAc to the hydroxyl group in mucin glycoproteins, there are other types of non-mucin O-glycans starting with O-fucose, O-xylose, and O-mannose, among others. In contrast to N-glycans, O-glycans are assembled, not processed. Mutations in O-glycan synthesis genes are responsible for a subset of congenital disorders of glycosylation (CDG).
CDG is a rapidly expanding genetic disease family (review in 6 ), with >100 types reported. Some 25 of these are pure Oglycosylation defects. Diagnosis of these diseases is performed by molecular testing. Since glycans play important roles in all organs and tissues, CDG are mostly multisystem disorders. The nervous system is mainly affected, 7 but other organs can also be severely compromised, including the liver 8 and heart, 9 as well as the immune system, 10 skeleton, 11 and eyes. 12 Morava et al. 12 described the ophthalmic involvement in N-glycosylation disorders. Here we review the ophthalmic aspects of CDG with pure O-glycosylation defects.
| O-GLYCOSYLATION AND THE HEALTHY EYE
The importance of O-glycosylation in eye development and physiology has been well documented. For example, in murine embryogenesis, a family of glycosyltransferases involved in O-glycosylation initiation (GalNAc-transferases) is not only expressed in the eye, but some isoforms are expressed differentially in eye layers. 13 Human eye biopsies have confirmed the specific expression pattern of these glycosyltransferases, as different isoforms were detected in a cell-layer-and cell-type-specific manner in corneal and conjunctival epithelia. An altered expression pattern of glycosyltransferases was observed in corneas undergoing a keratinization process, which may result in corneal opacification. 14 The protein O-linked-mannose β-1,2-Nacetylglucosaminyltransferase 1 (POMGNT1) protein, similar to GalNAc transferases, has an additional lectin domain, which modulates O-glycosylation of glycopeptide substrates in a mechanism resembling that of GalNAc transferases. 15 Mucins, known to form part of the tear film and other mucus secretions and occurring in corneal and conjunctival epithelia, are heavily O-glycosylated. 16 A comparative study on conjunctival epithelial cells of patients with non-Sjögren dry eye disease and healthy patients reported differences in the pattern of the H185 carbohydrate epitope of mucin 16 (MUC16). 17 O-glycans modulate mucin functions and are responsible for the viscoelastic properties of these proteins. 18 Mucins and their O-glycans play several roles, including clearance of debris and pathogens from the surface of the eye, hydration and lubrication, and prevention of pathogen adherence and colonization. 16 O-glycosylation in mucin contribute to maintaining the barrier function of the apical epithelium and-by impairing endocytosis-preventing the entry of microorganisms. 19 Defects in mucin Oglycosylation have been associated with several ocular disorders. 16 Recently, a new gene, HCG22 (MIM: 613918), encoding a novel, highly O-glycosylated mucin protein, was identified, with defects in this glycoprotein being associated with ocular hypertension, which can lead to glaucoma. 20 Pax-6 proteins, transcription factors involved in eye development, are O-glycosylated in neuroretinal cells of quails. 21 Alpha-dystroglycan (α-DG) is a cell-surface glycoprotein that plays a relevant role in extracellular matrix, actin, and cytoskeleton interactions. 22 α-DG O-mannosylation is essential for its laminin-binding properties.
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Differential α-DG glycosylation in eye development is suggested by the fact that α-DG antibody (IIH6) staining is undetectable in the retinas of new-born wild-type mice while being present during embryonic development. 24 Also, patients harboring defects in POMK, POMT1, POMT2, POMGNT1, FKRP, FKTN, TMEM5, B3GALNT2, ISPD, and LARGE, encoding O-glycosylation enzymes, show alterations in α-DG O-glycosylation. Since O-glycosylation seems to be a central mechanism in eye formation and function from early developmental stages, this systematic review aims to describe the prevalence and severity of ocular disorders in the congenital disorders of O-glycosylation.
| METHODS
This review was based on a search of the MEDLINE database using PubMed as the search engine. Selected keywords related to ocular disease were used in combination with selected pure O-glycosylation genes and disease designations (Table S1 and Fig. S1 for more details). Table 1 summarizes clinical data in patients with pure O-glycosylation disorders. Figure 1 depicts the molecular mechanisms and proteins associated with eye anomalies in O-glycosylation-deficient animal and in vitro models. 
| B3GALT6-CDG
Beta-1,3-galactosyltransferase polypeptide 6 (B3GALT6) is involved in the biosynthesis of the linkage region of glycosaminoglycans. Mutations in B3GALT6 are responsible for Ehlers-Danlos progeroid type 2 syndrome (MIM:615349), which causes short stature, craniofacial disproportion, and generalized osteopenia, but also hypermobile joints, muscular hypotonia, and loose elastic skin. Defects in B3GALT6 can also cause spondyloepimetaphyseal dysplasia with joint laxity type 1 (MIM:271640), characterized by skeletal involvement and respiratory dysfunction, resulting in early death. From the 30 B3GALT6-CDG patients reported, half had eye involvement. Blue sclerae was the most commonly found sign. 26, 29 Seven patients exhibited proptosis. 26 Malfait et al. 27 reported an 8-year-old boy who also had an excavation of both optic nerves. 27 Sellars et al. 28 reported a patient with anterior-segment eye anomalies not reported in previous phenotypes. 28 Additional eye anomalies are listed in Table 1 .
| B4GALT7-CDG
B4GALT7 encodes galactosyltransferase-I, an enzyme that catalyzes biosynthesis of the tetrasaccharide linkage region of proteoglycans. Mutations in this gene have been associated with two somewhat distinct phenotypes: a form of Ehlers-Danlos syndrome (MIM:130070) and Larsen of Reunion Island syndrome (LRS). 32 Clinical features in the 28 B4GALT7-CDG patients included joint laxity, short stature, bone abnormalities, skin hyperextensibility, hypotonia, a variable degree of developmental disability, and ocular involvement. Proptosis was present in 25, and in 10 patients, F I G U R E 1 Depicts the molecular mechanisms and proteins associated with eye anomalies in Oglycosylation-deficient animal and in vitro models additional ophthalmic findings were described. 30, 32, 33 Among them, a frequent ocular manifestation was hyperopia. 30, 31, 33, 34 Further eye manifestations are listed in Among them, a frequent ocular manifestation was hyperopia. 30, 31, 33, 34 Further eye manifestations are listed in Table 1 .
| B3GALTL -CDG
Defects in B3GALTL, encoding O-fucose-specific β-1,3-glucosyltransferase, cause Peters plus syndrome (MIM:261540), or B3GALTL-CDG. 35, 37 Clinical characteristics include variable degrees of developmental delay and facial dysmorphism and eye, skeletal (frequently associated with short stature), cardiac, and genitourinary involvement. At least 52 patients have been described. Anterior chamber (AC) abnormalities are constant, and the most common defect of this spectrum is Peters anomaly (PA). The latter comprises central corneal clouding, thinning of the posterior cornea, and iridocorneal adhesions. It is usually bilateral, and its expression ranges from mild to severe, with cataracts and congenital glaucoma being manifestations of the severe form. Other ocular signs are listed in Table 1 .
| B3GAT3-CDG
B3GAT3-CDG (MIM:245600) is caused by mutations in the gene that encodes the enzyme glucuronyltransferase-I (GlcAT-I), leading to impaired glycosaminoglycan synthesis. This syndrome (Larsen-like syndrome) consists of multiple joint dislocations, short stature, craniofacial dysmorphism, congenital heart defects, and mild developmental delay. Among the 8 described patients, 7 showed ophthalmic involvement. Proptosis and downslant palpebral fissures are quite common. 49, 50 Additional ophthalmologic signs are mentioned in Table 1 . 
| FKRP-CDG

| FKTN-CDG
Fukutin (FKTN) is a glycosyltransferase involved in Omannosylglycan synthesis. Defects in this protein cause FKTN-CDG (MIM:253800). Clinical variability and severity are quite broad. The most severe forms have been associated with Fukuyama congenital muscular dystrophy (FCMD), MEB disease, and WWS characterized by congenital muscular dystrophy associated with mental disability and ocular involvement. A total of 27 FKTN-CDG patients have been reported with eye problems. Four of them died before 5 months of age. 63, 64, [66] [67] [68] One of these 27 patients had a mild limb-girdle muscular dystrophy form (MIM:611588). Ocular abnormalities at the age of 16 were limited to strabismus. 70 Microphthalmia can be the first clinical sign 69 and is associated with poor prognosis. It is also the most frequently reported eye manifestation. 55, 61, [65] [66] [67] 69 Overall ocular manifestations are described in Table 1 .
| ISPD-CDG
ISPD encodes the isoprenoid synthase domain-containing protein, which is required for an efficient O-mannosylation of α-DG. The phenotypic spectrum of this disorder is that of the muscular dystrophy-dystroglycanopathies with and without brain and eye anomalies, the former including WWS and MEB disease (MIM:614643) and the latter encompassing limb-girdle muscular dystrophies (MIM:616052). Among the 50 patients identified in the literature, 24 suffered from eye defects. Among these, 17 received a WWS diagnosis. The most frequent symptoms were cataracts and microphthalmia. Retinal abnormalities have been described in isolation or in association with other defects, such AC anomalies. [71] [72] [73] [74] [75] Further clinical symptoms are detailed in Table 1 . ISPD encodes the isoprenoid synthase domaincontaining protein, which is required for an efficient Omannosylation of α-DG. The phenotypic spectrum of this disorder is that of the muscular dystrophydystroglycanopathies with and without brain and eye anomalies, the former including WWS and MEB disease (MIM:614643) and the latter encompassing limb-girdle muscular dystrophies (MIM:616052). Among the 50 patients identified in the literature, 24 suffered from eye defects. Among these, 17 received a WWS diagnosis. The most frequent symptoms were cataracts and microphthalmia. Retinal abnormalities have been described in isolation or in association with other defects, such AC anomalies. [71] [72] [73] [74] [75] Further clinical symptoms are detailed in Table 1 .
| LARGE-CDG
Acetylglucosaminyltransferase-like protein (LARGE) is a bifunctional glycosyltransferase with both xylosyltransferase and beta-1,3-glucuronyltransferase activities involved in the glycosylation of α-DG. Defects in this protein are associated with muscular dystrophy-dystroglycanopathies, with brain and eye anomalies (MIM:613154) or with mental retardation (MIM:608840). Eye involvement has been described in 16/18 patients with great variability and severity, including in 4 patients diagnosed with WWS. 65, 77, 80 Two siblings with severe eye anomalies died at the age of 6 and 2 months, respectively. 77 External eye anomalies, such as a narrow palpebral slit and proptosis, have been identified in a fetus. 80 Further ocular abnormalities are described in Table 1 . 
| POMGNT1-CDG
| POMK-CDG
POMK codes for the protein O-mannose kinase, which is responsible for mediating phosphorylation of the Omannosylglycan present in α-DG. POMK mutations have been described to result in two main clinical muscular dystrophy-dystroglycanopathy phenotypes either associated with brain and eye anomalies (MIM:615249) or with the limb-girdle form (MIM:616094). Eight patients have been reported; 5 of them showed eye involvement. [103] [104] [105] Reported eye manifestations have been quite heterogeneous (Table 1) . POMK codes for the protein O-mannose kinase, which is responsible for mediating phosphorylation of the O-mannosylglycan present in α-DG. POMK mutations have been described to result in two main clinical muscular dystrophy-dystroglycanopathy phenotypes either associated with brain and eye anomalies (MIM:615249) or with the limb-girdle form (MIM:616094). Eight patients have been reported; 5 of them showed eye involvement. [103] [104] [105] Reported eye manifestations have been quite heterogeneous (Table 1 ).
| POMT1-CDG
POMT1-CDG (MIM:236670) is due to a defect in the protein O-mannosyltransferase 1, involved in the first step of the O-mannosylglycan synthesis of α-DG in the ER. Patients generally present with brain and eye deformities, congenital muscular dystrophy, and profound cognitive impairment. One hundred and six patients have been described, and 61 of them had a visual impairment. In contrast with POMT2-CDG patients, POMT1-CDG patients with ocular involvement usually have a severe form of the disease, with WWS reported in 28 patients. 55, 56, 65, [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] From this cohort, 9 patients died before 4 years of age. 106, 107, [112] [113] [114] 116 Some POMT1 mutations have been found in cobblestone lissencephaly fetuses. 58, 88 The most commonly diagnosed ophthalmologic problem has been retinal dysplasia (see Table 1 for all ophthalmic anomalies).
| POMT2-CDG
POMT2-CDG, due to mutations in the gene encoding the protein O-mannosyltransferase 2, results in distinct congenital muscular dystrophy presentations ranging from eye and brain involvement (MIM:613150) to intellectual impairment (MIM:613156) and to a limb-girdle phenotype without central nervous system impairment (MIM:613158). At least 55 patients have been described, with ocular manifestations reported in 32. In the latter, POMT2 mutations have mainly been associated with a congenital muscular dystrophy with mild to moderate eye involvement, with ten reported cases of MEB. 56, 65, 78, [118] [119] [120] Seven POMT2-CDG patients presenting with WWS have been described with severe ocular manifestations 55, 117, 121 ; three died prior to 9 months of age.
117,121 POMT2 mutations have also been found in fetuses with cobblestone lissencephaly in association with a more severe phenotype. 58, 88 Myopia, cataracts, retinal dysplasia, and strabismus are common ocular manifestations (Table 1) .
| TMEM5-CDG
TMEM5 encodes the transmembrane protein 5, which is involved in biosynthesis of the phosphorylated Omannosylglycan present in α-DG. TMEM5 mutations give rise to a muscular dystroglycanopathy associated with brain and eye involvement as well as with cobblestone lissencephaly, referred to as TMEM5-CDG (MIM:615041). Thirteen patients have been diagnosed with TMEM5-CDG; seven of them showed eye abnormalities. By performing a genomewide linkage approach combined with an exome study, Vuillaumier-Barrot and colleagues detected TMEM5 mutations in nine fetuses with cobblestone lissencephaly; six manifested diffuse retinal dysplasia ( Table 1 ). The authors also found a high incidence of dysgenesis and neural tube defects in these patients, thus further defining the phenotype of this CDG. 72 For more ocular descriptions, see Table 1 .
| XYLT2 -CDG
Mutations in XYLT2, encoding the enzyme xylosyltransferase 2-involved in the first step of the biosynthesis of glycosaminoglycans-are the underlying cause of XYLT2-CDG (MIM:605822). This disease, also known as spondyloocular syndrome, is predominantly characterized by bone fragility and abnormalities, as well as eye problems and heart and hearing defects. Six of the 7 reported patients had cataracts 122, 123 (Table 1) .
| MOLECULAR MECHANISMS UNDERLYING THE EFFECT OF O-GLYCOSYLATION ON EYE DISORDERS
Pomgnt1-deficient and knockout mice displayed diverse ocular manifestations, including retinal dysfunction, dysplasia, and detachment, optic nerve dysfunction, and abnormal electroretinograms (ERGs), which authors related to reactive gliosis and reticular fibrosis in the retina. 125, 126 Loss of Pomgnt1 led to a milder effect on the lifespan of the mice. 125 In Pomgnt1 knockout mice embryos, the inner limiting membrane (ILM) had numerous disruptions and altered biomechanical properties, leading to protrusions of Müller cell glia and ectopic retinal ganglion cells in the vitreous, indicating that POMGNT1-mediated O-glycosylation is involved in maintaining structural integrity of the ILM. 127 Kuwabara and coworkers described a POMGNT1 molecular mechanism of action, having postulated that this enzyme attaches β-GlcNAc to clustered O-mannose sites and influences postphosphoryl modification of core M3 of α-DG. As core M3 is involved in laminin binding, POMGNT1 mutations may impair this process, therefore causing ILM disturbances.
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POMGNT1 messenger RNA (mRNA) and its encoded protein are expressed in the retina of various mammalian species, including humans, 128 and POMGNT1 mutations have been reported as the molecular cause of syndromic RP. 101, 102 Another study evaluated the role of POMGNT1 on a photoreceptor cell line and found that not only POMGNT1 but also POMT1 and POMT2 proteins were found both in the Golgi apparatus and in the nuclei. This raised the possibility that POMGNT1, besides having a major role in α-DG O-glycosylation in the cytoplasm, is also involved in the glycosylation of nuclear proteins, likely in association with POMT1/POMT2, thus expanding its cellular role.
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In mice, Large is expressed in the eye, 129, 130 and the consequences of mutations on eye function and structure have been assessed, resorting to the Large myd , Large vls , and
Large PB mice models, [129] [130] [131] in which Large proteins lack glycosyltransferase activity. In both cases, similarly to what happens in Pomgnt1 knockout mice, there is a disruption of the ILM associated with decreased laminin assembly, indicating that Large α-DG-mediated glycosylation is crucial for proper laminin binding. 130 Other retinal anomalies, like layering disruption, fibrous bundles and rosette-like structures, thinning of the outer retina, as well as vascular deformities such as persistent hyaloid vasculature (PHV), and altered ERGs have been reported. [129] [130] [131] In contrast with
Pomgnt1-deficient mice, in which a redistribution of the potassium channel Kir4.1 and aquaporin channel AQP4 occurs, 127 both of these α-DG-regulated proteins retain their perivascular location in Large-mutated mice. 130 LARGE overexpression rescues the dystrophic phenotype by restoring α-DG glycosylation 22 in the Large myd mice and also in cells of MEB and WWS individuals with POMGNT1 and POMT1 mutations. 23, 132 LARGE overexpression has also restored functional α-DG, 132 suggested to be achieved via modification of N-glycans and/or mucin O-glycans on α-DG. 133 Willer and collaborators found that LARGE overexpression did not have a similar effect on POMT1-and ISPD-deficient cells. 73 However, the impact of LARGE overexpression on eye cells has not yet been determined. These findings indicate glycosylation restoration or enhancement as a possible therapeutic strategy for these diseases, although LARGE-mediated α-DG glycosylation effectiveness may be conditioned by gene mutations or even by mutation types.
A work developed on zPOMT1 and zPOMT2 expression and function in zebra fish embryos revealed that both genes were highly expressed in the eye during embryonic development. Silencing of zPOMT2 resulted in abnormal eye pigmentation. 134 In the mouse model, Pomt1 mRNA has also been detected in the eye throughout evolving stages of embryonic development. 135, 136 Loss of Pomt1 proved to be embryonic lethal, 136 which is in accordance with the frequent association of POMT1 mutations and WWS. A similar phenotypic spectrum as that seen in FKRP-CDG patients was observed in zebra fish downregulated for zFKRP expression during embryonic development. zFKRPdeficient morphants had small eyes. [137] [138] [139] Histological analysis revealed a disorganized retinal layering. 138 Injection of either human or fish FKRP mRNA restored the normal phenotype of morphants, including eye size. Viral injection of FKRP in mice with fkrp mutations rescued the muscular dystrophy phenotype and induced increased levels of α-DG in skeletal and cardiac muscle. 140 Kawahara and colleagues analyzed the effects of different mutations associated with distinct phenotypic severity in humans and found that eye defects present in C318Y mutants resembled those seen in WWS human patients. 137 In mice, the effects of mutated fkrp forms were evaluated, revealing reduced levels of α-DG, ILM disruption leading to the intrusion of ectopic cells in the vitreous body 24, 141, 142 due to alterations in the laminin-α1 axis, 24 thinner inner and outer nuclear layer, smaller optic nerves, and corneal opacification.
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Since fktn knockout in mice resulted in embryonic lethality, 143 fktn-deficient chimeric mice had to be generated to study the effects of fktn in the eye. 144 Eye findings in these mice included corneal anomalies, namely: corneal thickening, opacification, inflammation, and degeneration with vascular infiltration; retinal alterations, such as loss of laminar structure of the retina, retinal folding, and retinal detachment; as well as adhesion of the lens and cornea and abnormal ERGs. 144 In zebra fish, both zFKRP and zFKTN silencing led to abnormalities in eye vasculature, with a more severe phenotype in the case of zFKTN downregulation. 139 In fktn-deficient mice, and in contrast to what had been previously observed in mice and human cells, 132 LARGE overexpression did not rescue the dystroglycanopathy phenotype. Coexpression of LARGE and FKTN in embryonic stem (ES) cells caused a large increase in the levels of functional α-DG, indicating that for LARGE to have a therapeutic effect, FKTN needs to be active. 22 Supporting these results are the findings of Yoshida-Morigushi and coworkers, who postulated that LARGE and FKTN share a common pathway in the assembly of the laminin-binding moiety onto the phosphorylated O-linked mannose of α-DG.
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Recently, ISPD was described as synthetizing CDP-ribitol, following which FKRP and FKTN can catalyze the transfer of a ribitol phosphate to α-DG. Surprisingly, in ISPD-mutated cells, medium supplementation with ribitol partially rescued α-DG glycosylation. 145 Additionally, in an elegant study using the mouse model (ISPD L79*/L79* ), described as lacking mature glycans necessary for dystroglycan to bind to laminin, Clements and colleagues showed that defective expression of ISPD impairs laminin deposition and binding, disrupting the ILM early in the embryonic period. This disruption leads to a disorganized eye formation, with retinal neurons protruding into the vitreous space, and to ineffective guidance of retinal ganglion cell axons to the optic nerve. These mutants also exhibited abnormal vasculature, including PHV. 146 The knockdown of B3GALTL resulted in a significant decrease in the levels of thrombospondin-1 (TSP1), 147 a glycoprotein responsible for matricellular remodeling involved in corneal angiogenesis and homeostasis, and present in many other ocular cell types both during the embryonic period and adulthood, including the aqueous humor, lens, and vitreous body. 148, 149 TPS1 has been implicated in several mechanisms and eye disorders. In fact, uncontrolled or anomalous corneal vasculature can lead to corneal opacity. Also, the fact that TPS1 has been found in other eye compartments supports the hypothesis of the role of this protein in maintaining optical clarity. Besides its antiangiogenic activity, TPS1 has also been found to play an important role in ocular wound healing and immunological response, thus influencing cell migration. Abnormal neural crest cell migration to the posterior cornea is implicated in the formation of PA, the most common AC defect present in B3GALTL-CDG patients; therefore, one might hypothesize that low TPS1 levels may result in impaired cellular migration ability, leading to PA development. [148] [149] [150] The array of functions and cellular types in which TPS1 acts suggests that B3GALTL mutations may lead to ocular dysfunction by impairing TPS1 function.
| CONCLUSION
Our review shows that 60% of CDG with a pure Oglycosylation defect present with eye involvement, thus reinforcing the importance of ocular signs in these diseases. A total of 370 O-glycosylation CDG patients have been reported to have some degree of ophthalmologic impairment. Among these CDG, those with the highest frequency of patients with eye disorders are B3GALTL-CDG, LARGE-CDG, B3GAT3-CDG, and XYLT2-CDG. Ninetyeight percent of B3GALTL-CDG patients have been described to have ocular manifestations, with the majority of patients severely affected. PA-normally in association with other AC defects-is a distinctive ophthalmologic entity that should suggest a diagnosis of CDG. B3GALTL-regulated Oglycosylation is also crucial for AC morphology and physiology. Among the O-glycosylation CDG with ocular features, B4GALT7-CDG has the lowest incidence of ophthalmic manifestations. Nevertheless, 36% (10/28) of these patients are visually impaired. Proptosis is a characteristic trait (25/28 patients) of B4GALT7-CDG. In B3GAT3-CDG patients, proptosis is also a very common feature (6/8 patients). In some CDG, the occurrence of eye disease or severity of ocular involvement is associated with graver clinical outcomes, namely, in FKTN-CDG, FKRP-CDG, ISPD-CDG, POMK-CDG, POMGNT1-CDG, and POMT2-CDG. This review contributes to the identification of ophthalmic disease patterns in some CDG; for example, hyperopia is very common in B4GALT7-CDG, cataracts are frequent in XYLT2-CDG patients, microphthalmia is a hallmark of FKTN-CDG, while in most CDG caused by defective α-DG glycosylation, retinal dysfunction-namely, retinal dysplasia and detachment-are frequently found. Findings in humans are in line with those described in animal and in vitro models, suggesting that proper α-DG glycosylation is of paramount importance for retinal development and function. In POMGNT1-CDG patients, as in B3GALTL-CDG patients, AC defects are very common, reinforcing the importance of O-glycosylation for AC function and formation. The recent correlation of POMGNT1 mutations with nonsyndromic RP, and localization of this protein (in association with both POMT1 and POMT2) in the nucleus of a photoreceptor cell line, highlights the importance of these genes and proteins in human eye disease. A vast number of CDG patients present with congenital eye malformations, which emphasizes the importance of glycosylation in eye formation during embryonic development.
Additionally, this review identified O-mannosylation defects as those with the highest incidence of eye disorders (POMT1, POMT2, POMGNT1, POMK, B3GALTN2, ISPD, FKNT, FKPR, TMEM5, and LARGE). Besides their involvement in O-mannosylation, all of these enzymes are also responsible for adding glycans to α-DG. This finding reinforces the pivotal role of α-DG for proper ocular function and integrity and the importance of its posttranslational modification (PTM, O-mannosylation).
In contrast with the predominance of ophthalmologic manifestations in O-mannosylation defects (associated with the phenotype of muscular dystroglycanopathies), most Oglycosylation CDG without known ocular features are related to syndromes characterized by bone, joint, and/or skin abnormalities (eg, O-Xyl glycosylation CDG, such as EXT1-CDG and CHSY1-CDG; O-GlcNAc glycosylation, namely, EOGT-CDG or O-Fuc glycosylation, like POFUT1-CDG and LFNG-CDG). The exception among OFuc glycosylation defects is B3GALTL-CDG, which shows important eye anomalies. However, many B3GALTL-CDG also present with bone alterations, which points toward the relevance of O-glycosylation in bone formation and function, and underlies the ubiquity of this PTM in cellular processes and types, explaining the multiplicity of signs and symptoms in CDG patients. However, the fact that B3GALTL-CDG patients present both eye and skeletal issues may also suggest that other types of Oglycosylation CDG may exhibit minor or less-frequent ophthalmic problems that are overlooked due to their reduced clinical significance and/or the rarity of these CDG.
Although some molecular mechanisms explaining the impact of glycosylation anomalies-particularly of Oglycosylation defects-on eye disorders have been identified, much remains to be elucidated. Various in vitro and in vivo models have been established, facilitating the discovery of further relationships and interactions among proteins as well as potential therapies. Some recent discoveries in these models show that glycosylation is implicated in regulating synaptic signaling in the retina. For example, pikachurin, an extracellular-matrix-like protein that binds to α-DG, has been found at cell dendrites to photoreceptors and is strongly regulated by glycosylation in a tissue-specific manner in retinal cells. 151 A diabetic rat model revealed that although transcription of synaptophysin-a glycoprotein involved in the neuronal synapse-is up-regulated, the posttranslational mechanism of retinal synaptophysin is dysregulated. This results in higher levels of its "immature" and highly glycosylated form that, in turn, leads to an accelerated degradation of this protein and, ultimately, could explain some of the ophthalmologic signs often seen in diabetic patients. 152 Restoration of α-DG glycosylation (in particular cases attainable by LARGE overexpression or ribitol supplementation) shows promise as a potential therapy and thus needs investigation.
To conclude, we believe this review on eye involvement in pure O-glycosylation disorders contributes to guiding research, diagnosis, and treatment of these patients. To conclude, we believe this review on eye involvement in pure O-glycosylation disorders contributes to guiding research, diagnosis, and treatment of these patients. 
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